Masitinib

Product ID M0374

Cas No. 790299-79-5

Purity ≥98%

Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description
Product Info
Shipping and Storage
Downloads
References
Custom Order

Description

Masitinib is an anticancer chemotherapeutic and anti-inflammatory compound used in veterinary medicine. Masitinib inhibits c-Kit and PDGFR, increasing survival time in the treatment of mast cell tumors and other cancers. In vitro, masitinib increases levels of caspases 3 and 7, inducing apoptosis. Masitinib also decreases airway inflammation and edema in feline allergic asthma models and also decreases the patient-rated severity of multiple sclerosis in clinical settings. Masitinib also exhibits potential efficacy against Alzheimer’s disease when given as an adjunct therapy, slowing cognitive decline.

Product Info

Cas No.	790299-79-5
Purity	≥98%
Formula	C₂₈H₃₀N₆OS
Formula Wt.	498.64
Chemical Name	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
IUPAC Name	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1, 3-thiazol-2-yl)amino]phenyl]benzamide
Synonym	AB1010; Masatinib; Masitinib (AB1010); Masivet
Appearance	Gray to off white powder

Shipping and Storage

Store Temp	Ambient
Ship Temp	Ambient

Downloads

Info Sheet	M0374 Info Sheet PDF

References

Smrkovski OA, Essick L, Rohrbach BW, et al. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Vet Comp Oncol. 2013 Jul 12. [Epub ahead of print]. PMID: 23845124.

Fahey CE, Milner RJ, Kow K, et al. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anticancer Drugs. 2013 Jun;24(5):519-26. PMID: 23466652.

Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012 Jun 12;12:36. PMID: 22691628.

Lee-Fowler TM, Guntur V, Dodam J, et al. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158(4):369-74. PMID: 22487554.

Cadot P, Hensel P, Bensignor E, et al. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Vet Dermatol. 2011 Dec;22(6):554-64. PMID: 21668810.

Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011 Apr 19;3(2):16. PMID: 21504563.